Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stem Cell Sciences, a provider of stem cells and stem cell technologies, has signed a master service agreement of up to five years with Pfizer Limited, the UK operating unit of the pharmaceutical company Pfizer, Inc.
Subscribe to our email newsletter
Under the terms of the agreement, Stem Cell Sciences (SCS) will provide research services, cell lines, media and reagents to support Pfizer’s R&D efforts in this important field.
Alastair Riddell, CEO of SCS, said: “The opening of Pfizer’s new regenerative medicine research facility in Cambridge, UK, is very important for stem cell research and reinforces the UK’s position as an international centre of excellence. We are therefore very pleased to be able to support Pfizer’s efforts to advance biomedical research under our new agreement.”